Search results
Results from the WOW.Com Content Network
Tata 1mg, previously 1mg, [3] is a healthcare platform based in Gurugram, India. It provides services, including e-pharmacy , diagnostics , e-consultation , and health content. It was founded in April 2015 by Prashant Tandon, Gaurav Agarwal, and Vikas Chauhan.
February 2021 – BigBasket (68%) by Tata Digital; June 2021 – 1mg (55%) by Tata Digital; October 2021 – Air India, Air India Express and 50% stake in Air India SATS for ₹ 18,000 crore (US$2.1 billion). January 2022 – Nilachala Ispat Nigam Ltd, $1.5 billion; June 2023 – Kaleyra, Inc by Tata Communications for $100 million. [19]
A MedPlus outlet in Hyderabad. MedPlus was founded in 2006 by Madhukar Gangadi. The company's first store was launched in Hyderabad. [8] Initially operating under the Aushadhi brand name, it was rebranded as MedPlus after the opening of the first 48 stores.
Tata Translational Cancer Research Center (TTTRC) is a dedicated research facility embedded within Tata Medical Center. It was established in 2014, and moved to dedicated facilities in April 2018. The institute is housed within a dedicated academic space and is spread over 3 floors.
PharmEasy competes with other e-pharmacy companies including Netmeds (which was acquired by Reliance Industries), 1mg (acquired by Tata Group), Apollo 24x7 and Amazon Pharmacy. [11] The Ken questioned the company's positioning as a unified healthtech player and referred to the company's story as "more confusing than convincing". [12]
Tata Research Development and Design Centre (TRDDC) is a software research centre in Pune, India, established by Tata Group's TCS in 1981. TRDDC undertakes research in Machine Learning , Software Engineering , Process Engineering and Systems Research.
Natarajan Chandrasekaran (born 2 June 1963) is an Indian businessman, and the chairman of Tata Sons and Tata Group. [1] [2] He was chief operating officer (COO) and executive director of Tata Consultancy Services (TCS), where in 2009, he became chief executive officer (CEO). [3] [4] He was also the chairman of Tata Motors and Tata Global ...
BGR-34 (Blood Glucose Regulator-34) [1] is an Ayurvedic-derived product that is sold in India as an over-the-counter pill for the management of type 2 diabetes.It was developed in 2015 by two government-owned laboratories and launched commercially in 2016.